Last reviewed · How we verify
metronomic adjuvant chemotherapy with capecitabine
metronomic adjuvant chemotherapy with capecitabine is a Small molecule drug developed by Chongqing University Cancer Hospital. It is currently in Phase 3 development.
At a glance
| Generic name | metronomic adjuvant chemotherapy with capecitabine |
|---|---|
| Sponsor | Chongqing University Cancer Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC (PHASE3)
- Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
- Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer (PHASE3)
- tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)
- EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) (PHASE2)
- Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer (PHASE2, PHASE3)
- Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metronomic adjuvant chemotherapy with capecitabine CI brief — competitive landscape report
- metronomic adjuvant chemotherapy with capecitabine updates RSS · CI watch RSS
- Chongqing University Cancer Hospital portfolio CI
Frequently asked questions about metronomic adjuvant chemotherapy with capecitabine
What is metronomic adjuvant chemotherapy with capecitabine?
metronomic adjuvant chemotherapy with capecitabine is a Small molecule drug developed by Chongqing University Cancer Hospital.
Who makes metronomic adjuvant chemotherapy with capecitabine?
metronomic adjuvant chemotherapy with capecitabine is developed by Chongqing University Cancer Hospital (see full Chongqing University Cancer Hospital pipeline at /company/chongqing-university-cancer-hospital).
What development phase is metronomic adjuvant chemotherapy with capecitabine in?
metronomic adjuvant chemotherapy with capecitabine is in Phase 3.